Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Chemical Research in Toxicology

• Publication date

  2010-08-16

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/tx100023cPMID 20666396
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Analysis of organometal(loid) compounds in environmental and biological samples.

  2010cited by this paper
• Development of an ultraperformance liquid chromatography/mass spectrometry method to quantify cisplatin 1,2 intrastrand guanine-guanine adducts.

  2009cited by this paper
• The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research.

  2008cited by this paper
• In vivo detection of DNA adducts induced by cisplatin using capillary HPLC–ICP-MS and their correlation with genotoxic damage in Drosophila melanogaster

  2008cited by this paper
• Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin

  2008cited by this paper
• The resurgence of platinum-based cancer chemotherapy

  2007cited by this paper
• Development of a liquid chromatography-electrospray ionization tandem mass spectrometry method for detecting oxaliplatin-DNA intrastrand cross-links in biological samples.

  2007cited by this paper
• Speciation studies of cis-platin adducts with DNA nucleotides via elemental specific detection (P and Pt) using liquid chromatography-inductively coupled plasma-mass spectrometry and structural characterization by electrospray mass spectrometry

  2006cited by this paper
• Specific adducts recognised by a monoclonal antibody against cisplatin-modified DNA.

  2005cited by this paper
• Measurement of DNA adducts in cells exposed to cisplatin.

  2004cited by this paper
• Application of HPLC-ICP-MS to speciation of cisplatin and its degradation products in water containing different chloride concentrations and in human urine

  2003cited by this paper
• A comparison of the quantitative methods for the analysis of the platinum-containing anticancer drug [cis-[amminedichloro(2-methylpyridine)]platinum(II)] (ZD0473) by HPLC coupled to either a triple quadrupole mass spectrometer or an inductively coupled plasma mass spectrometer.

  2003cited by this paper
• Mass spectrometry of cis-diamminedichloroplatinum(II) adducts with the dinucleosidemonophosphates d(ApG), d(GpG) and d(TpC) in an ion trap.

  2002cited by this paper
• How Does Cisplatin Kill Cells

  2000cited by this paper
• Comparison of features of human breast cancer cell lines and their corresponding tumors.

  1999cited by this paper
• Comparison of features of human lung cancer cell lines and their corresponding tumors.

  1999cited by this paper
• 32P-postlabeling assay for the quantification of the major platinum-DNA adducts.

  1999cited by this paper
• Determination of Biotransformation Products of Platinum Drugs in Rat and Human Urine

  1997cited by this paper
• Improved 32P-postlabelling assay for the quantification of the major platinum-DNA adducts.

  1997cited by this paper
• Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.

  1996cited by this paper
• In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.

  1996cited by this paper
• Immunochemical quantitation of adducts induced in DNA by cis-diamminedichloroplatinum (II) and analysis of adduct-related DNA-unwinding.

  1985cited by this paper
• Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation.

  1985cited by this paper

• Collision-induced ribosome degradation driven by ribosome competition and translational perturbations

  2025influential citation
• Integrated Electrochemical Aptasensor Array toward Monitoring Anticancer Drugs in Sweat.

  2024cites this paper
• The current status in computational exploration of Pt(IV) prodrug activation by reduction.

  2023cites this paper
• Recent developments in chemodrug-loaded nanomedicines and their application in combination cancer immunotherapy

  2023cites this paper
• Induction chemotherapy in head and neck cancers - old actors, new horizons

  2022cites this paper
• Three-Photon AIE Pt(II) Complexes as Cysteine-Targeting Theranostic Agents for Tumor Imaging and Chemotherapy.

  2022cites this paper
• Development of Comprehensive Ultraperformance Liquid Chromatography-High Resolution Mass Spectrometry Assays to Quantitate Cisplatin-Induced DNA-DNA Cross-Links

  2022cites this paper
• Lost by Transcription: Fork Failures, Elevated Expression, and Clinical Consequences Related to Deletions in Metastatic Colorectal Cancer

  2022cites this paper
• Is the cytotoxic activity of phenanthriplatin dependent on the specific size of the phenanthridine ligand π system?

  2021cites this paper
• Intracellular Delivery of Oxaliplatin Conjugate via Cell Penetrating Peptide for the Treatment of Colorectal Carcinoma in vitro and in vivo.

  2021cites this paper
• Anticancer Activity, DNA Binding, and Photodynamic Properties of a N∧C∧N-Coordinated Pt(II) Complex.

  2021cites this paper
• Detection of the level of DNA cross-linking with cisplatin by electrochemical quartz crystal microbalance

  2020cites this paper
• Rationalization of the superior anticancer activity of Phenanthriplatin. An in depth computational exploration.

  2020cites this paper
• DNA–affibody nanoparticle delivery system for cisplatin-based breast cancer chemotherapy

  2019cites this paper
• IL-2 Induces Transient Arrest in the G1 Phase to Protect Cervical Cancer Cells from Entering Apoptosis

  2019cites this paper
• A novel screening method for transition metal‐based anticancer compounds using zebrafish embryo‐larval assay and inductively coupled plasma‐mass spectrometry analysis

  2019cites this paper
• Toosendanin mediates cisplatin sensitization through targeting Annexin A4/ATP7A in non-small cell lung cancer cells

  2018cites this paper
• Speciation and element-specific detection

  2017cites this paper
• Tunable Signal-Off and Signal-On Electrochemical Cisplatin Sensor.

  2017cites this paper
• Cisplatin resistance in cell models: evaluation of metallomic and biological predictive biomarkers to address early therapy failure.

  2017cites this paper
• In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors

  2017cites this paper
• A species-specific double isotope dilution strategy for the accurate quantification of platinum–GG adducts in lung cells exposed to carboplatin

  2017cites this paper
• Ethaselen: a novel organoselenium anticancer agent targeting thioredoxin reductase 1 reverses cisplatin resistance in drug-resistant K562 cells by inducing apoptosis

  2017cites this paper
• Selective speciation improves efficacy and lowers toxicity of platinum anticancer and vanadium antidiabetic drugs.

  2016cites this paper
• A molecular assembly that crawls on a solid substrate with a metabolic-like process

  2016cites this paper
• EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations

  2016cites this paper
• DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine

  2016cites this paper
• Electrochemical Detection of Platinum(IV) Prodrug Satraplatin in Serum.

  2015cites this paper
• Predicting of Effective Dose as Biomarker for Cytotoxicity Using Partial Least Square-Fourier Transform Infrared Spectroscopy (PLS_FTIR)

  2015cites this paper
• Analytical approaches to investigating metal-containing drugs.

  2015cites this paper
• Recent progress of ICP-MS in the development of metal-based drugs and diagnostic agents

  2014cites this paper
• A quantitative mass spectrometry-based approach for assessing the repair of 8-methoxypsoralen-induced DNA interstrand cross-links and monoadducts in mammalian cells.

  2013cites this paper
• In vitro studies on cisplatin focusing on kinetic aspects of intracellular chemistry by LC-ICP-MS.

  2013cites this paper
• Anticancer metallodrug research analytically painting the “omics” picture—current developments and future trends

  2013cites this paper
• Nuclease digestion and mass spectrometric characterization of oligodeoxyribonucleotides containing 1,2-GpG, 1,2-ApG, and 1,3-GpXpG cisplatin intrastrand cross-links.

  2013cites this paper
• Speciation of Trace Elements

  2013cites this paper
• Chapter 22 – Speciation and Element-Specific Detection

  2013cites this paper
• A complex of cyclohexane-1,2-diaminoplatinum with an amphiphilic biodegradable polymer with pendant carboxyl groups.

  2012cites this paper
• Interstrand Crosslinks - Induction and repair

  2012cites this paper
• Therapy-induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues.

  2012cites this paper
• Hyphenated techniques as tools for speciation analysis of metal-based pharmaceuticals: developments and applications

  2012cites this paper
• The Fanconi anaemia pathway orchestrates incisions at sites of crosslinked DNA

  2012cites this paper
• DNA damage by reactive species: Mechanisms, mutation and repair

  2012cites this paper
• Quantitation of DNA adducts by stable isotope dilution mass spectrometry.

  2012cites this paper
• Relationships between cisplatin-induced adducts and DNA strand-breaks, mutation and recombination in vivo in somatic cells of Drosophila melanogaster, under different conditions of nucleotide excision repair.

  2012cites this paper
• On the complexity and dynamics of in vivo Cisplatin-DNA adduct formation using HPLC/ICP-MS.

  2012cites this paper
• Metal-based antitumour drugs in the post-genomic era: what comes next?

  2011cites this paper
• Investigation of DNA adducts formed in cells and clinical tumour biopsies following exposure to platinum-containing anticancer drugs

  2011cites this paper
• Speciation of oxaliplatin adducts with DNA nucleotides.

  2011cites this paper
• Atomic spectrometry update. Elemental speciation

  2009cites this paper